Special Issues

Special Issue Title: Atrial fibrillation and ischemic heart disease

· Print Special Issue Flyer

· Deadline for manuscript submissions:  15 August 2021


Special Issue Editor

Guest Editor


        Associate Professor Matteo Anselmino, MD PhD

       "A.O.U. Città della Salute e della Scienza di Torino" Hospital, Division of Cardiology, Department of Medical Sciences, University of Turin, Italy

Website | E-Mail

Interests: Catheter Ablation; Cardiovascular Disease; Atrial Fibrillation; Cardiac Electrophysiology; Heart Failure; Clinical Cardiology; Arrhythmias; Electrocardiogram


Special Issue Information

Dear Colleagues,


Atrial Fibrillation (AF) is the most common arrhythmia and is becoming a major public health burden in developed and developing countries. On top of increasing mortality, AF induces several disabling symptoms such as palpitations, decreased exercise tolerance, and pulmonary congestion. In addition, AF patients may experience ischemic heart disease (IHD) symptoms and signs, attributable to alterations of the myocardial perfusion, even in the absence of classical obstructive coronary artery disease. Despite the relevant epidemiology of both conditions, however, the mechanisms proposed and the effects of the relationship of AF and IHD are, to date, under-assessed.

Aim of the present Special Issue is to invite experts in the field to explore the following aspects of the AF/IHD correlation:

Goal of this issue: 

- atrial fibrillation and ischemic heart disease epidemiology

- heart rhythm and coronary blood flow physiology
- computational models of coronary circulation during atrial fibrillation
- anticoagulation in patients with atrial fibrillation and ischemi heart disease
- Clinical case of ischemic heart disease in patients with atrial fibrillation

Thanks to your great contributions, in the opinion of the Guest Editor, the present Special Issue will provide valuable insights.


Matteo Anselmino

Guest Editor

 

Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.



Keywords

Atrial fibrillation; Irregular heart rhythm; Coronary blood flow physiology; Myocardial perfusion; Non-obstructive coronary artery disease; Epidemiology; Computational modelling


Share This Special Issue

     

Planned Papers

Title: Atrial Fibrillation and Coronary Artery Disease: a review on the optimal use of oral anticoagulants
Authors: Elisabetta Toso, Filippo Angelini and Pier Paolo Bocchino



Please wait a minute...
For Selected: Toggle Thumbnails
Prognostic implications of atrial fibrillation in patients with stable coronary artery disease: a systematic review and meta-analysis of adjusted observational studies
Andrea Saglietto, Vittorio Varbella, Andrea Ballatore, Henri Xhakupi, Gaetano Maria De Ferrari, Matteo Anselmino
Reviews in Cardiovascular Medicine    2021, 22 (2): 439-444.   DOI: 10.31083/j.rcm2202049
Abstract211)   HTML24)    PDF(pc) (819KB)(270)       Save
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. Despite the frequent coexistence with coronary artery disease (CAD), the prognostic independent implication of AF in patients with stable CAD remains controversial. Our aim was to perform a pairwise meta-analysis of adjusted observational studies comparing cardiovascular outcomes in patients with stable CAD with and without concomitant AF, in search of AF-specific prognostic implications. We performed random effect meta-analysis of binary outcome events in studies comparing stable CAD patients with versus without AF providing risk estimates adjusted for confounding variables. Literature search was performed in PubMed/MEDLINE and Google Scholar. Death was the primary endpoint of the analysis, while myocardial infarction, coronary revascularization and stroke secondary endpoints. 5 studies were included in the meta-analysis, encompassing a total of 30230 stable CAD patients (2844 with AF, 27386 without AF). Stable CAD patients with AF presented an independent increased risk of death (HR 1.39, 95% CI: 1.17–1.66) and stroke (HR 1.88, 95% CI: 1.45–2.45) compared to those without AF. Instead, risk of myocardial infarction (HR 0.90, 95% CI: 0.66–1.22) and coronary revascularization (HR 0.96, 95% CI: 0.79–1.16) did not differ in stable CAD patients with and without the arrhythmia. In patients with stable CAD, AF exerts an independent negative prognostic effect, increasing the risk of death and stroke. However, the small number of eligible studies included in this analysis highlights the astonishing lack of data regarding prognostic implications of concomitant AF in patients with stable CAD.
Supplementary Material | Related Articles | Metrics
Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants
Pier Paolo Bocchino, Filippo Angelini, Elisabetta Toso
Reviews in Cardiovascular Medicine    2021, 22 (3): 635-648.   DOI: 10.31083/j.rcm2203074
Abstract273)   HTML48)    PDF(pc) (164KB)(521)       Save
Atrial fibrillation (AF) represents the most prevalent supraventricular arrhythmia in adults population and up to 15% of AF patients undergo percutaneous coronary intervention (PCI) for coronary artery disease (CAD) during their life. While oral anticoagulants (OACs) exert a protective effect in the setting of stroke prevention and systemic embolization in AF patients, patients undergoing PCI are recommended to receive dual antiplatelet therapy (DAPT) to reduce the risk of cardiovascular death, recurrent myocardial infarction and stent thrombosis. When these two scenarios coexist, as all antithrombotic regimens are burdened by an increase in bleeding risk, antithrombotic regimen and therapy duration must be cautiously tailored on individual patients' characteristics after attentive assessment of ischemic and bleeding risks. Non-vitamin K oral anticoagulants (NOACs), directly inhibiting either thrombin or factor Xa of the coagulation cascade, have progressively replaced warfarin as first choice OACs in several scenarios; recently, randomized controlled trials have compared antithrombotic regimens including NOAC molecules vs vitamin K antagonists in AF patients undergoing PCI to explore the efficacy and safety of NOACs in this setting. These studies have provided a deeper understanding of antithrombotic therapy after PCI in AF patients and have been promptly implemented by the most recent guidelines on AF and CAD management. The aim of the present review was to summarize the current available literature on the perils and benefits of individual OAC molecules in AF patients with acute and/or chronic coronary syndromes in order to provide guidance on the optimal use of OACs in these complex scenarios.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3